Therefore, the combination of TMB with other TME markers such as PD-L1 level, CD8+ tumor infiltrating lymphocytes and MHC profile can help select the best possible candidates that will benefit from PD-L1/PD-1 therapy. This evidence concerns the gene HLA-C and neoplasm.